SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE™ Stent

Now CE Marked: 1-month DAPT Indication for High Bleeding Risk Patients

XIENCE™ Stent

XIENCE 28 showed that XIENCE™ Stent with 1-month DAPT had no increase in ischemic events and a significantly lower rate of severe bleeding (BARC 3-5) compared with 6-month DAPT. These data were used to support the CE Mark for a 1-month DAPT indication in High Bleeding Risk Patients.

 

XIENCE™ STENT is proven safe with 1-month and 3-month DAPT in HBR patients.1

1-Month DAPT Indication for High Bleeding Risk Patients

XIENCE 28 vs XIENCE 90 - First Look

XIENCE 28 & XIENCE 90 Trial Results

1-Month DAPT Indication for High Bleeding Risk Patients

1-Month DAPT Indication for High Bleeding Risk Patients

Optimal DAPT Duration Video

XIENCE 28 vs XIENCE 90 - First Look

Xience 28 & Xience 90 Trial Results Video

XIENCE 28 & XIENCE 90 Trial Results

XIENCE 28 Results1

pci xience 28 all-mi chart


XIENCE™ Stent with 1-month DAPT showed no increase in ischemic events versus 6-month DAPT — all death or MI.1

XIENCE 28 met its primary non-inferiority endpoint and included over 1600 high-bleeding risk patients.1

pci xience 28 barc chart


XIENCE™ Stent with 1-month DAPT had a significantly lower rate of severe bleeding versus 6-month DAPT. (BARC 3-5).1

For BARC 2-5 — XIENCE™ Stent with 1-month DAPT showed numerically lower bleeding rate versus 6-month DAPT.1

Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.

XIENCE™ Stent shows low ST rate and is significantly more thromboresistant than other DES.1,2

pci xience 28 stent thrombosis chart


XIENCE™ Stent with 1-month DAPT showed no increase in ST versus 6-month DAPT.1

XIENCE™ Stent with 1-month DAPT had a low rate of Definite/Probable stent thrombosis of 0.3% for the 1-month DAPT group.1

XIENCE™ Stent is significantly more thromboresistant than other DES.2

pci xience stent fluoro

XIENCE™ Stent's fluoropolymer is significantly more thromboresistant than other DES2

XIENCE™ Stent shows significantly (p<0.01) less platelet adhesion vs. other DES.2

XIENCE 90 Results1

pci xience 90 all mi chart


XIENCE™ Stent with 3-month DAPT showed no increase in ischemic events versus 12-month DAPT — all death or MI.1

XIENCE 90 met its primary non-inferiority endpoint and included over 2000 high-bleeding risk patients.1

pci xience 90 barc chart


XIENCE™ Stent with 3-month DAPT had a significantly lower rate of severe bleeding versus 12-month DAPT. (BARC 3-5).1

For BARC 2-5 -- XIENCE with 3-month DAPT showed numerically lower bleeding rate versus 12-month DAPT.1

Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.

pci xience 90 stent thrombosis chart


XIENCE™ Stent with 3-month DAPT met its performance goal for ST.1

XIENCE 90 met its performance goal for ST and showed a low rate of Definite/Probable stent thrombosis of 0.2% for the 3-month DAPT group.1

References

 

  1. XIENCE Skypoint - Instructions for Use. Mehran R, et al. J Am Coll Cardio Intv. 2021;14:1870-1883
  2. Sato Y, et al. Int J Caridol. 2021;338:42-49.

MAT-2009430 v6.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0